GleamWall
中文EN

MGTX MeiraGTx Holdings plc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1735438 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,365.9%
TTM net income YoY146.4%
TTM EPS YoY141.2%
Revenue 3-yr CAGR291.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin44.8%
Net margin19.5%
FCF margin-0.7%
EBITDA margin47.8%

Returns

ROE89.7%
ROA26.0%
ROIC (approx.)—
Asset turnover1.34x

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.00x
Current ratio4.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio25.6%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$4.81M$321.43M$293,000$75.36M$410,000$3.69M$1.93M$21.39M
R&D expense$39.32M$57.83M$31.98M$30.81M$32.53M$33.49M$32.78M$23.98M
SG&A expense$11.95M$12.01M$8.93M$17.60M$13.62M$12.31M$9.36M$17.09M
Operating income-$49.88M$244.43M-$40.82M$26.47M-$46.05M-$44.79M-$41.60M-$31.49M
Interest expense—$3.51M$2.85M$3.06M$3.06M$3.03M$3.04M$3.41M
Income tax$613,000$2.36M$0$0$0$0$0$0
Net income-$51.21M$160.72M-$46.31M$15.09M-$50.51M-$38.80M-$39.98M-$39.40M
EBITDA-$47.03M$247.25M-$37.81M$29.59M-$42.90M-$41.60M-$38.52M-$28.42M
EPS (basic)-0.531.76-0.57—-0.62-0.48-0.51—
EPS (diluted)-0.531.71-0.57—-0.62-0.48-0.51—
Weighted avg. shares (diluted)96.88M93.81M81.30M—80.95M80.59M79.03M—
Balance sheet
Cash & equivalents$184.65M$143.17M$71.54M$65.93M$17.11M$34.42M$68.61M$105.67M
Receivables——$3.26M$3.00M$2.81M$2.32M$734,000$707,000
Inventory—————$314,000$607,000$385,000
Current assets$242.35M$218.35M$96.20M$91.76M$34.17M$47.08M$79.89M$123.52M
PP&E, net$96.87M$100.33M$102.57M$105.47M$107.65M$110.82M$104.41M$102.88M
Intangibles$17,000$421,000$494,000$578,000$653,000$742,000$773,000$821,000
Total assets$411.69M$396.45M$244.66M$244.43M$189.47M$198.72M$224.01M$269.75M
Current liabilities$52.40M$58.10M$176.13M$122.56M$152.92M$53.44M$52.37M$60.78M
Total liabilities$196.47M$180.67M$302.79M$250.22M$230.03M$195.76M$190.91M$201.92M
Shareholders' equity$215.08M$215.57M-$58.13M-$5.79M-$40.56M$2.96M$33.10M$67.83M
Shares outstanding97.62M94.19M81.45M81.12M80.48M80.45M79.42M78.40M
Cash flow statement
Operating cash flow-$24.55M-$38.54M$17.81M$46.63M-$12.21M-$43.95M-$36.83M-$23.28M
Capital expenditure$1.73M$332,000$2.01M$272,000$610,000$1.23M$1.71M$1.22M
Free cash flow-$26.28M-$38.87M$15.80M$46.36M-$12.82M-$45.18M-$38.54M-$24.49M
Investing cash flow-$1.73M-$23.64M-$2.26M-$1.09M-$547,000-$761,000-$1.71M-$1.22M
Financing cash flow$67.77M$133.90M-$10.11M$5.33M-$219,000$5.45M$1.71M$4.24M
Depreciation & amortization$2.85M$2.82M$3.01M$3.12M$3.15M$3.19M$3.08M$3.07M
Stock-based compensation$7.66M$3.78M$3.65M$5.60M$5.95M$5.66M$4.89M$6.12M
Share buybacks$0$0$18.19M—————

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.